Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Inventiva SA IVA

Healthcare Biotechnology
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. The company develops Lanifibranor, a novel pan-peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses. It also develops TGF-ß, a pre-clinical program for the treatment of idiopathic pulmonary fibrosis. The company was incorporated in 2011 and is headquartered in Daix, France.


NDAQ:IVA - Post by User

Inventiva SA
Bullboard Posts
Next >>
User Avatar Image
(1)
•••
  • indoubtgetoutX
Post by indoubtgetouton Jul 14, 2020 1:32pm
183 Views
Post# 31266366

DOG - IPO on USA a bust

DOG - IPO on USA a bustIPO investors hoodwinked by underwriters.   What a poor showing....down $6 from first day of trading on USA markets.   Jefferies and Guggenheim are supposed to be good brokers but they sacrificed their clients on this one.....MOVE YOUR ACCOUNTS FROM JEFFERIES AND GUGGENHEIM...TEACH THEM A LESSON!!
Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities